SPC193
Venetoclax, þ.e. 4-(4-{[2-(4-klórfenýl)-4,4-dímetýlsýklóhex-1-en-1-ýl]metýl}píperazín-1-ýl)-N-({3-nítró-4-[(tetrahýdró-2H-pýran-4-ýlmetýl)amínó]fenýl}súlfónýl)-2-(1H-pyrróló[2,3-b]pýridín-5-ýloxý)benzamíð
Status:
VeittApplication date:
26.5.2017Application published:
15.6.2017Grant published:
15.5.2018
Max expiry date:
6.12.2031Medicine name:
VenclyxtoMedicine for children:
No
Timeline
Today
26.5.2017Application
15.6.2017Publication
15.5.2018Registration
6.12.2031Expires
Marketing license
IS authorization number:
EU/1/16/1138/003-004; EU/1/16/1138/005-007; EU/1/16/1138/001-002
Foreign authorization number:
EU/1/16/1138
Owner
Name:
AbbVie Manufacturing Management Unlimited CompanyAddress:
70 Sir John Rogerson´s Quay, Dublin 2 IE
Name:
Genentech, Inc.Address:
1 DNA Way, South San Francisco, CA US
Name:
The Walter and Eliza Hall Institute of Medical ResearchAddress:
1G Royal Parade, Parkville, Victoria AU
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113 Reykjavík
Patent
Number:
EP2435432